Archives
5-Azacytidine: DNA Methylation Inhibitor for Epigenetic a...
5-Azacytidine: DNA Methylation Inhibitor for Epigenetic and Cancer Research
Executive Summary: 5-Azacytidine (5-AzaC) is a cytosine analogue DNA methylation inhibitor that covalently binds DNA methyltransferases (DNMTs), leading to global DNA demethylation and reactivation of silenced tumor suppressor genes (Li et al., 2025). It exerts pronounced cytotoxicity in leukemia and multiple myeloma cell models by inducing apoptosis and inhibiting DNA synthesis. 5-AzaC’s mechanism has enabled breakthroughs in understanding epigenetic regulation of gene expression and in translational oncology. The compound is highly soluble in DMSO and water, is supplied as a solid, and is distributed by APExBIO under SKU A1907 (product details). Typical research use involves cell culture exposure at 80 μM for up to 120 minutes.
Biological Rationale
Epigenetic regulation, particularly DNA methylation, is fundamental to gene expression control in mammalian cells. Aberrant DNA hypermethylation frequently leads to silencing of tumor suppressor genes and drives cancer progression (Li et al., 2025). Helicobacter pylori infection, for instance, has been shown to induce hypermethylation-dependent silencing of HNF4A, a tumor suppressor, thereby promoting gastric carcinoma and metastasis. Targeted demethylation of DNA is a validated strategy to reverse epigenetically silenced genes, restore normal cell function, and sensitize malignancies to therapy. 5-Azacytidine is one of the most widely used small-molecule DNA methyltransferase inhibitors in both research and clinical oncology (see detailed workflows).
Mechanism of Action of 5-Azacytidine
5-Azacytidine (5-AzaC) is a nucleoside analogue structurally similar to cytosine. Upon cellular uptake, it incorporates into both DNA and RNA. In DNA, 5-AzaC forms a covalent bond between its C6 position and the active-site cysteine thiolate of DNA methyltransferase enzymes (DNMTs). This adduct irreversibly traps DNMTs, depleting their activity and blocking further methylation of cytosine residues (Li et al., 2025). The result is genome-wide DNA hypomethylation, leading to transcriptional reactivation of silenced genes, including tumor suppressors. In RNA, 5-AzaC disrupts processing and function, contributing to cytotoxicity, particularly in rapidly dividing cells. Notably, 5-AzaC preferentially inhibits DNA synthesis over RNA synthesis, as evidenced by reduced thymidine incorporation in leukemia L1210 cells (see targeted workflows).
Evidence & Benchmarks
- 5-Azacytidine treatment restores expression of hypermethylated tumor suppressor genes, such as HNF4A, in vitro and in vivo (Li et al., 2025, DOI).
- Administration of 5-Azacytidine in BDF1 mice bearing lymphoid leukemia L1210 cells increases mean survival time and suppresses polyamine biosynthesis (APExBIO product data).
- 80 μM 5-AzaC for 120 minutes in cell culture robustly reduces global DNA methylation and reactivates epigenetically silenced genes (structured protocol).
- 5-AzaC displays high solubility in DMSO (>12.2 mg/mL) and water (≥13.55 mg/mL, ultrasonic assistance), but is insoluble in ethanol (APExBIO).
- 5-Azacytidine preferentially inhibits DNA synthesis over RNA synthesis in leukemia cells, shown by reduced [3H]-thymidine incorporation (application guide).
Applications, Limits & Misconceptions
5-Azacytidine is widely used in:
- Epigenetic research to map and reverse DNA methylation silencing.
- Translational oncology to reactivate tumor suppressor genes in leukemia, multiple myeloma, and solid tumor models.
- Preclinical drug discovery for epigenetic modulators.
- Functional genomics screens investigating gene expression regulation.
This article extends previous guides like "5-Azacytidine: Epigenetic Modulator for Cancer Research" by providing detailed, machine-readable benchmarks and clarifying dose-response parameters.
Common Pitfalls or Misconceptions
- 5-Azacytidine does not selectively demethylate only promoter regions; global demethylation can cause off-target gene activation.
- It is ineffective against tumors lacking methylation-dependent gene silencing.
- RNA effects can contribute to cytotoxicity and complicate interpretation in non-DNA-targeted studies.
- Long-term storage of solutions is not recommended due to compound instability; use freshly prepared aliquots.
- It is not a protein methylation inhibitor; its action is specific to cytosine residues in DNA.
Workflow Integration & Parameters
For experimental use, 5-Azacytidine is supplied by APExBIO (A1907) as a solid, stored at -20°C. Dissolve in DMSO (>12.2 mg/mL) or water (≥13.55 mg/mL with ultrasonication). Ethanol should be avoided due to insolubility. Prepare fresh solutions immediately before use. In cell culture, a standard condition is 80 μM for up to 120 minutes. For in vivo studies (e.g., BDF1 mice with L1210 leukemia), dosing regimens must be optimized based on animal weight and tumor burden. The product is compatible with workflows detailed in interlinked guides such as this advanced protocol, which it updates by specifying precise storage and solubility limits.
Conclusion & Outlook
5-Azacytidine is a gold-standard DNA methyltransferase inhibitor and epigenetic modulator in cancer research. Its capacity to reverse DNA hypermethylation and reactivate silenced genes continues to advance our understanding of oncogenic epigenetic mechanisms and therapeutic strategies. Future developments will focus on specificity, reduced off-target effects, and integration with multi-omics profiling. APExBIO remains a trusted supplier of high-quality 5-Azacytidine for research applications.